Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit

Primary or acquired resistant mechanisms prevent the employment of individualized therapy with target drugs like the mTOR inhibitor everolimus (EVE) in hepatocellular carcinoma (HCC). The current study evaluated the effect of 1,25(OH)(2)Vitamin D (VitD) treatment on EVE sensitivity in established mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Provvisiero, Donatella Paola, Negri, Mariarosaria, de Angelis, Cristina, Di Gennaro, Gilda, Patalano, Roberta, Simeoli, Chiara, Papa, Fortuna, Ferrigno, Rosario, Auriemma, Renata Simona, De Martino, Maria Cristina, Colao, Annamaria, Pivonello, Rosario, Pivonello, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690984/
https://www.ncbi.nlm.nih.gov/pubmed/31406139
http://dx.doi.org/10.1038/s41598-019-48081-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690984/
https://www.ncbi.nlm.nih.gov/pubmed/31406139
http://dx.doi.org/10.1038/s41598-019-48081-9

Ejemplares similares